TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04681417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan or Melphalan + Topotecan
Description: IAC: 2-6 cycles every 1 month (number based on the local tumor evolution), performed using radio-guided catheterization and delivery at the ostium of the ophthalmic artery, in neuroradiology operating room, and under General Anesthesia (GA). IAC will be administered at the Fondation Rothschild Hospital in collaboration with the Interventional Neuroradiology team.

Intervention type: DRUG
Group type: OTHER
Intervention: etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy
Description: 2 to 6 cycles of combined etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy : thermotherapy and/or cryotherapy and/or iodine-125 plaques and/or intravitreal chemotherapy injections

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin administered on Day 1
Description: Chemothermotherapy : Intravenous injection by carboplatin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermotherapy (local treatment)
Description: Thermotherapy after carboplatin administered on Day 1

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermotherapy (local treatment)
Description: Thermotherapy after carboplatin administered on Day 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy (local treatment)
Description: Cryotherapy (local treatment)

Intervention type: DEVICE
Group type: OTHER
Intervention: Cryotherapy (local treatment)
Description: Cryotherapy (local treatment)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iodine-125 plaques (local treatment)
Description: Iodine-125 plaques (local treatment)

Intervention type: DEVICE
Group type: OTHER
Intervention: Iodine-125 plaques (local treatment)
Description: Iodine-125 plaques (local treatment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Melphalan chemotherapy injections (local treatment)
Description: Intravitreal Melphalan chemotherapy injections (local treatment)

Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal Melphalan chemotherapy injections (local treatment)
Description: Intravitreal Melphalan chemotherapy injections (local treatment)
Study: NCT05477862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinically Designed Improvisatory Music
Description: Clinically Designed Improvisatory Music (CDIM) is a form of improvised music based on calm-inducing sound parameters which brought relief to our cohort of neurology patients.
Study: NCT06001385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV or PO pre-transplant as part of conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV pre-transplant as part of conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV pre-transplant as part of conditioning regimen
Study: NCT06357130

Intervention type: OTHER
Intervention: Questionnaire
Description: A flyer with QR code leading to the online questionnaire will be sent to trans associations and healthcare networks for distribution to the target population.
Study: NCT06001385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV pre-transplant as part of conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV pre-transplant as part of conditioning regimen
Study: NCT04749446

Intervention type: OTHER
Intervention: Treatment of Breast Sarcoma according clinical practice (includes drugs, surgery or any other received treatments)
Description: This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments~Reorder Outcome Measures
Study: NCT05532137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-12HR app
Description: The 'feedback' e-12HR version: This version of the application allows to calculate the Mediterranean Diet Serving Score (MDSS) index; additionally, this version is designed to promote the Mediterranean diet with two specific automatic functions:~1. Evaluation of the user's MDSS index.~2. Identification of the food groups for which the user has not fulfilled the Mediterranean diet recommendations (in addition, this version also provided the user the consumption recommendations established for these food groups).
Study: NCT06001385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV pre-transplant as part of conditioning regimen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
Description: Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
Description: Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
Description: Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0
Study: NCT05236543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: Subjects will receive single oral dose only on Day 1 and Day 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Subjects will receive Itraconazole orally on Days 8 followed by dosing from Day 9 to Day 17.
Study: NCT06001385

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
Description: Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0
Study: NCT06483022

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BELIEVE IPE Training
Description: The IPC training will be delivered to health team members who provide intrapartum and/or postpartum maternity care at each facility. Individuals with roles as maternity care providers, nurses, lactation consultants or doulas whose primary inpatient clinical assignment is maternity care will be included in the training. The training will consist of a pre-session module (about 60 minutes), a 90-minute interprofessional collaboration session, delivered using virtual reality head-sets, and post-session modules (about 60 minutes). The pre- and post-session modules will be delivered through an online learning platform.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Prior to implementation of the IPC training, birthing people at the facilities will receive treatment-as-usual
Study: NCT05597839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF9001
Description: Immunotherapy agent targeting NK cells.
Study: NCT06001385

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
Description: Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Transplant Cyclophosphamide
Description: Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours.~First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Transplant Cyclophosphamide
Description: Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours.~First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.
Study: NCT05597839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF9001
Description: Immunotherapy agent targeting NK cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF9001
Description: Immunotherapy agent targeting NK cells.
Study: NCT06132776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HiToP 191 PNP
Description: High tone therapy
Study: NCT06001385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Transplant Cyclophosphamide
Description: Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours.~First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.
Study: NCT06132776

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo device
Description: Placebo therapy
Study: NCT04765202

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AG Tx
Description: The control treatment is meshed autograft applied to a FT burn area

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SOMA Tx
Description: The experimental treatment is more widely meshed autograft than the AG Tx site applied to a FT burn area and covered with SOMA
Study: NCT06001385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Transplant Cyclophosphamide
Description: Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours.~First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Transplant Cyclophosphamide
Description: Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours.~First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at Day + 90 and finished by Day +180.
Study: NCT05696808

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHPD
Description: The intervention is planned as a supervised dietary supplementation, with a goal of restricting the calorie intake to 25 Kcal/Kg BW/day, with a protein intake of 1 gm/Kg BW/day i.e., around 15 % of total calories from protein, 35% from fats and 50% from carbohydrates. Major portion of the carbohydrates is vegetables, fruits and then cereals (high fiber cereals), more amount of tomato and amla at least 200 gm in a day, protein requirements are met by mainly legumes like chick pea black - (kala chana) and moong sprouts besides dals. Lean meats and egg whites would be allowed as the non-vegetarian source. Milk products used are only milk and buttermilk, curd (excluding paneer). Major source of oil would be mustard oil only.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Western Diet
Description: The intervention is planned with a goal of restricting the calorie intake to 40 Kcal/Kg BW/day, around 10-15 % of total calories from protein, 30-35% from fats and 55-60% from carbohydrates. Major portion of the carbohydrates is Western fast food comprising of pizza and burger, French fries, sweets, muffins, cakes, chocolates, sugar sweetened beverages.
Study: NCT05597839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Anti-PD-1 immunotherapy agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Anti-PD-1 immunotherapy agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: Anti-PD-1 immunotherapy agent
Study: NCT04381897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: Oral solution for N-acetyl cysteine is prepared in syringes and provided to the participants along with instructions on how to administer them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: Oral solution for N-acetyl cysteine is prepared in syringes and provided to the participants along with instructions on how to administer them.
Study: NCT05597839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: Anti-PD-1 immunotherapy agent
Study: NCT04381897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: NAC Placebo-matching solution is prepared in syringes and provided to the participants along with instructions on how to administer them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: NAC Placebo-matching solution is prepared in syringes and provided to the participants along with instructions on how to administer them.
Study: NCT06593314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: EHR Alert
Study: NCT06603402

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose involved-field radiotherapy combined with immunochemotherapy
Description: low-dose involved-field radiotherapy combined with immunochemotherapy
Study: NCT04768686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX475
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT04920318

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: tDCS + language therapy
Description: In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: sham TDCS + language therapy
Description: sham control will be applied with language therapy to the same regions as active TDCS.
Study: NCT05875805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Serious Illness Care Program
Description: The adapted telehealth Serious Illness Care Program is a multilevel intervention engaging the patient, caregiver, clinician, and system. It consists of tools, training, and system change. Tools include: 1) The Serious Illness Conversation Guide for clinicians; and 2) Education materials for patients on the importance of Serious Illness Conversations (Patient Preparation Pamphlet) and of the involvement of caregivers (Family Communication Guide).

Intervention type: OTHER
Group type: OTHER
Intervention: Education Control
Description: Education materials developed by the NCI on Communication in Cancer Care (PDQ®) - Patient Version
Study: NCT06262607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLE-400
Description: Topical CLE400 gel 0.28% administered once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical vehicle gel administered once daily
Study: NCT04850027

Intervention type: PROCEDURE
Intervention: TME+Lateral lymph node dissection.
Description: TME and lateral lymph node dissection is performed in rectal cancer patients with lateral lymph node short diameter ≥ 5 mm.
Study: NCT05641467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: OculusQuest 2 128GB brand virtual reality glasses will be used in our research. OculusQuest 2 128GB is the original all-in-one gaming system for virtual reality. It can only be used as desired with the VR headset and controllers. It adapts to its environment. In this way, it can be played standing and sitting in small and large areas. When glasses will be used on another pregnant women within the scope of COVID-19 measures, disinfection will be provided with 'DiverseyOxivir Plus (hydrogen peroxide)' surface disinfectant. Before the episiotomy repair, the video glasses will be opened, the video will be adjusted to suit the woman. In order for the repair method to be the same for all women, It will be planned to use absorbable, synthetic, braided, sterile surgical thread produced from 1-0 polyglactin.
Study: NCT05540171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral health education and instructions/training for self-oral care
Description: Education intervention
Study: NCT05653362

Intervention type: DEVICE
Group type: OTHER
Intervention: Coconut Oil
Description: Coconut oil was applied to the patients' abdomen during the ultrasound to serve as a conducting medium. When applied topically, coconut oil is not absorbed systemically by the subject and will not affect the fetus. There are no studies showing a potential risk of the use of topical coconut oil in pregnancy. Subjects with a coconut allergy will be excluded from this study due to risk of allergic reaction.

Intervention type: DEVICE
Group type: OTHER
Intervention: Coconut Oil
Description: Coconut oil was applied to the patients' abdomen during the ultrasound to serve as a conducting medium. When applied topically, coconut oil is not absorbed systemically by the subject and will not affect the fetus. There are no studies showing a potential risk of the use of topical coconut oil in pregnancy. Subjects with a coconut allergy will be excluded from this study due to risk of allergic reaction.

Intervention type: DEVICE
Group type: OTHER
Intervention: Commercial Ultrasound Gel
Description: Room-temperature Aquasonic 100 (Parker Laboratories, Inc., Fairfield, NJ) applied to patients' abdomen during the ultrasound to serve an another conducting medium.

Intervention type: DEVICE
Group type: OTHER
Intervention: Commercial Ultrasound Gel
Description: Room-temperature Aquasonic 100 (Parker Laboratories, Inc., Fairfield, NJ) applied to patients' abdomen during the ultrasound to serve an another conducting medium.
Study: NCT05414695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real acupuncture
Description: Device with acupuncture needles 25 × 0.22 mm, Cloud \& Dragon Medical Device Co, Ltd, China. Needle penetrates the skin 4 mm

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Device with acupuncture needles 25 × 0.22 mm, Cloud \& Dragon Medical Device Co, Ltd, China. Needle does not touch the skin.
Study: NCT06323889

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Alternate Day Fasting
Description: Participants are instructed to fast every other day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time-Restricted Eating
Description: Participants are instructed to limit food intake to two main meals consumed in maximum 8 hours per day

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight-loss counseling
Description: Participants will receive nutrition counseling to structure their main meals according to the plate model for weight-loss and to reduce number of consumed plates.
Study: NCT06615167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALZGUARD
Description: A digital therapeutic(DTx) application that uses artifical intelligence to analyze cognitive function and provide a diagnosis of dementia.
Study: NCT06615622

Intervention type: DIETARY_SUPPLEMENT
Intervention: Placebo
Description: Thiotacid 300 mg tab once/day
Study: NCT06571552

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Plasma Exchange followed by Double Filtration Plasmapheresis
Description: Double Filtration Plasmapheresis followed by Single Plasma Exchange
Study: NCT06045286

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: High- and Low-dose radiotherapy
Description: High-dose radiotherapy (6-8Gy×3-7F) followed by low-dose radiotherapy (0.5-1.4Gy×3-7F) starting within 7 days after completion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitors
Description: Immunotherapy (Zimberelimab) is given every three weeks within one week after the end of high-dose radiotherapy.
Study: NCT06615492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Routine ECMO
Description: Routine intraoperative venoarterial ECMO during lung transplant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-demand ECMO
Description: Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative venoarterial ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities :~1. Inability to maintain adequate hemodynamics and stable perfusion despite volume resuscitation and vasopressor administration and in the absence of readily correctable cause~2. Inability to tolerate pulmonary artery clamping~3. Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching~4. Inadequate exposure to the surgical field~5. The transplant team is concerned about the ability to maintain organ perfusion or ventilate with a lung protective strategy, even if the aforementioned criteria are unmet.~6. Concerns about donor lung quality and a desire to protect the implanted lung from single lung perfusion
Study: NCT06669871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shirt-A
Description: A dress shirt of a specific design will be provided to the participants, in which weight of the front side will be double than the back side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shirt-A
Description: A dress shirt of a specific design will be provided to the participants, in which weight of the front side will be double than the back side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shirt-B
Description: A dress shirt of a simple design will be provided to the participants, in which weight of the front side will be equal to the back side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shirt-B
Description: A dress shirt of a simple design will be provided to the participants, in which weight of the front side will be equal to the back side.
Study: NCT06613789

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b
Description: self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b
Description: self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen.
Study: NCT06005142

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eriomin
Description: Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day capsule of Eriomin for 12 weeks.